218 related articles for article (PubMed ID: 34334296)
1. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Manglaviti S; Brambilla M; Signorelli D; Ferrara R; Lo Russo G; Proto C; Galli G; De Toma A; Occhipinti M; Viscardi G; Beninato T; Zattarin E; Bini M; Lobefaro R; Massa G; Bottiglieri A; Apollonio G; Sottotetti E; Di Mauro RM; Trevisan B; Ganzinelli M; Fabbri A; de Braud FGM; Garassino MC; Prelaj A
Clin Lung Cancer; 2022 Jan; 23(1):e17-e28. PubMed ID: 34334296
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis.
Miyashita K; Karayama M; Inoue Y; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kono M; Matsui T; Niwa M; Koda K; Toyoshima M; Matsushima S; Matsuura S; Asada K; Fujii M; Kusagaya H; Matsuda H; Inui N; Suda T
BMC Pulm Med; 2021 Oct; 21(1):309. PubMed ID: 34600514
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
5. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
8. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Manglaviti S; Bini M; Apollonio G; Zecca E; Galli G; Sangaletti S; Labianca A; Sottotetti E; Brambilla M; Occhipinti M; Proto C; Prelaj A; Signorelli D; De Toma A; Viscardi G; Beninato T; Mazzeo L; Bottiglieri A; Leporati R; Fotia G; Ganzinelli M; Portararo P; Garassino MC; de Braud FGM; Lo Russo G; Torri V; Ferrara R
Lung Cancer; 2023 Dec; 186():107417. PubMed ID: 37918061
[TBL] [Abstract][Full Text] [Related]
9. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
10. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
11. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
12. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
Mao S; Zhou F; Liu Y; Yang S; Chen B; Xu J; Wu F; Li X; Zhao C; Wang W; Liu Q; Yu X; Jia K; Shao C; Zhou C; Gao G; Ren S
Cancer Immunol Immunother; 2022 Jan; 71(1):219-228. PubMed ID: 34097116
[TBL] [Abstract][Full Text] [Related]
13. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
14. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
Xu Z; Li T; Hu X; Hao X; Xing P; Li J
Thorac Cancer; 2021 Sep; 12(17):2360-2368. PubMed ID: 34268872
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S; Takada K; Shimokawa M; Jinnnouchi M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Cancer Immunol Immunother; 2021 Jun; 70(6):1745-1753. PubMed ID: 33389013
[TBL] [Abstract][Full Text] [Related]
17. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
18. Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.
Zhao Q; Li B; Xu Y; Wang S; Zou B; Yu J; Wang L
Cancer Med; 2021 Sep; 10(18):6291-6303. PubMed ID: 34390218
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
20. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
